Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study reports a 15-year-old girl from a visceral leishmaniasis-endemic area in Greece presenting with various symptoms, including high fever, morning joint pain, and blood in urine, eventually leading to findings like rash, anemia, and kidney issues. Results are not detailed in this abstract.

This case report describes a 34-year-old kidney transplant patient who developed a unique skin condition linked to cyclosporine, characterized by flesh-colored papules, and introduces "cyclosporine induced folliculodystrophy" as a term for this condition.

This review addresses alopecia areata, emphasizing its autoimmune nature, unpredictable course, and lack of preventive or curative treatments, while noting standard and emerging therapies such as topical steroids and Janus kinase inhibitors.

This article highlights that early and high-dose corticosteroid therapy, along with immunosuppressive agents, is crucial for managing Vogt-Koyanagi-Harada disease, and emerging biological therapies may benefit refractory cases.

This case report suggests that Rituximab and high-dose immunosuppressive therapy may be effective for treating severe cutaneous lupus erythematosus like TEN-like ACLE, leading to remission and recovery.

In this case report, the authors highlight a 20-month-old girl with nephrotic syndrome who experienced severe alopecia due to an accidental high dose of cyclosporine; her hair regrew after the drug was stopped.

This study observed that dermatological patients using certain immunosuppressants, like azathioprine and high-dose prednisolone, had a reduced humoral immune response to the Sinovac-CoronaVac COVID-19 vaccine compared to those without such treatments.

In this case report, a 40-year-old woman with systemic lupus erythematosus developed Type B Insulin Resistance Syndrome, characterized by severe hyperglycemia despite high insulin doses, requiring immunosuppressive therapy to manage refractory symptoms.

This review discusses fixed drug eruption (FDE) potentially linked to finasteride and emphasizes dermatologists' need to recognize its possible occurrence due to the drug's widespread use, but reports no new clinical results.

This study found that topical application of cyclosporin A and FK506 induces new hair growth in mice, while ascomycin and rapamycin do not, suggesting hair induction is not due to immunosuppression.

In this case report, a patient with severe atopic dermatitis experienced significant improvement with dupilumab after other treatments, including immunosuppressive agents, failed to control the disease.

In this study on C3H/HeJ-engrafted mice, a single injection of BMD-1141 significantly increased anagen hair follicle counts and enhanced hair regrowth compared to daily high-dose ruxolitinib, suggesting it stimulates hair growth by influencing the hair cycle rather than altering immune response.

Cyclosporin A and FK506 can start new hair growth in mice, but ascomycin and rapamycin cannot.

This chapter reviews studies on the side effects of cytostatics and immunosuppressive drugs, detailing various toxicities such as cardiovascular, pulmonary, and neurotoxicity, but provides no new clinical results.

In this reported case, an immunosuppressive regimen including tacrolimus and mycophenolate mofetil was associated with a total regression of hidradenitis suppurativa activity over one year, while cyclosporine alone had no effect.

This review discusses various syndromes of severe insulin resistance, their biochemical and clinical features, and potential therapeutic options, but it reports no new clinical results.

This report describes the unexpected development of alopecia areata in kidney-pancreas transplant recipients undergoing cyclosporine-based immunosuppressive therapy, suggesting a complex relationship between the treatment and disease.

This article reviews methotrexate's pharmacokinetics and toxicity, emphasizing the role of urinary excretion and leucovorin in avoiding most toxic reactions; it provides no new clinical results.

This systematic review reports that "COVID toes" and other skin manifestations can be initial signs of COVID-19, and advises immunosuppressive therapy adjustments only for infected or at-risk patients.

This article discusses the factors influencing anticancer therapeutic regimens and reviews mechanisms of action and side effects of major chemotherapeutic agents without reporting new research findings.

This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.

This study reports an increase in the frequency and variety of skin conditions associated with COVID-19, noting that milder cases often present with pernio-like lesions, while severe cases may involve livedo racemosa, retiform purpura, and acral ischemia.

Different substances affect hair and skin cell growth in various ways.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

This case study reports that adding adalimumab to a 12-year-old VKH patient's treatment allowed for ocular inflammation remission, vision improvement, and corticosteroid tapering, suggesting escalation of immunosuppression may be critical in pediatric VKH cases.

This article provides guidance on managing systemic lupus erythematosus without presenting new research findings, emphasizing the role of clinical nurse specialists and the importance of lifestyle modifications and appropriate medication regimens.

This article discusses the roles of pediatrics and dermatology departments at Yale University School of Medicine, but reports no specific clinical results.

This report presents a rare case of a patient with type Wong dermatomyositis who also exhibits clinical and histologic features of porokeratosis, potentially signaling associated malignancies in dermatomyositis patients.

Transplant patients often get skin problems, with treatments varying by condition.

This article discusses the autoimmune pathogenesis of alopecia areata and reviews the use of immunosuppressive therapies in its treatment, but it does not provide new clinical results.